Physician profile
Gurleen Pasricha
NPI 1891041893
$3,741.91
in general payments reported to CMS, 2019-2025
56 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $65.55 · 2021: $279 · 2022: $357 · 2023: $748 · 2024: $1,020 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.98 |
| Education | $296.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $320.33 | 2022-2023 | Cabometyx |
| Incyte Corporation | $309.08 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Geron Corporation | $221.03 | 2025 | Rytelo |
| Astrazeneca Pharmaceuticals LP | $219.37 | 2021-2025 | Lynparza, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $166.33 | 2023-2025 | Keytruda, Reblozyl, Welireg |
| E.R. Squibb & Sons, L.L.C. | $166.28 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $137.05 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Abbvie INC. | $121.95 | 2024-2025 | |
| Genzyme Corporation | $115.08 | 2021-2024 | |
| Eisai INC. | $111.29 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.87 | 2023-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $98.21 | 2019-2025 | |
| Daiichi Sankyo INC. | $94.23 | 2021-2024 | Enhertu, Vanflyta |
| Array Biopharma INC | $74.79 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Genentech USA, INC. | $74.49 | 2021-2024 | Lunsumio, Columvi, Polivy |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurleen Pasricha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.